| Mrs Shannon Morrish Manojlovic, APRN | |
|
5801 Crossings Blvd, Antioch, TN 37013-3130 | |
| (615) 941-8501 | |
| Not Available |
| Full Name | Mrs Shannon Morrish Manojlovic |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 5801 Crossings Blvd, Antioch, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851805865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 23557 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Diagnostic Imaging Pc | 7315848140 | 545 |
News Archive
Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.
Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.
Researchers from Birmingham University have designed a drug similar to the illicit drug Ecstasy (3,4-methylenedioxymethamphetamine) that could be used to treat leukemia, lymphoma and myeloma after making it 100 times more effective at suppressing growth.
arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease clinical trial.
› Verified 1 days ago
| Entity Name | Advanced Diagnostic Imaging Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093741464 PECOS PAC ID: 7315848140 Enrollment ID: O20040115000677 |
News Archive
Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.
Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.
Researchers from Birmingham University have designed a drug similar to the illicit drug Ecstasy (3,4-methylenedioxymethamphetamine) that could be used to treat leukemia, lymphoma and myeloma after making it 100 times more effective at suppressing growth.
arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease clinical trial.
› Verified 1 days ago
| Entity Name | Pain Management Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902804271 PECOS PAC ID: 7012812043 Enrollment ID: O20080530000028 |
News Archive
Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.
Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.
Researchers from Birmingham University have designed a drug similar to the illicit drug Ecstasy (3,4-methylenedioxymethamphetamine) that could be used to treat leukemia, lymphoma and myeloma after making it 100 times more effective at suppressing growth.
arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease clinical trial.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Shannon Morrish Manojlovic, APRN 3024 Business Park Cir, Goodlettsville, TN 37072-3132 Ph: (615) 239-2018 | Mrs Shannon Morrish Manojlovic, APRN 5801 Crossings Blvd, Antioch, TN 37013-3130 Ph: (615) 941-8501 |
News Archive
Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.
Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.
Researchers from Birmingham University have designed a drug similar to the illicit drug Ecstasy (3,4-methylenedioxymethamphetamine) that could be used to treat leukemia, lymphoma and myeloma after making it 100 times more effective at suppressing growth.
arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease clinical trial.
› Verified 1 days ago
Mrs. Rachel Benz Grace, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4200 Murfreesboro Pike, Antioch, TN 37013 Phone: 615-501-3500 | |
Jennifer Friley, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4676 Chutney Dr, Antioch, TN 37013 Phone: 615-554-3879 | |
Mrs. Joelle M Krizner, N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-941-8501 Fax: 615-941-8102 | |
Candius G Loggins, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-851-9401 | |
Miss Natsai Laurah Zhou, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2929 Old Franklin Rd, # 809, Antioch, TN 37013 Phone: 615-243-0776 | |
Michelle Aubrie Feneck, RN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2788 Murfreesboro Pike, Antioch, TN 37013 Phone: 714-329-7594 | |
Mrs. Mendy A Hicks, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-941-8501 Fax: 615-941-8502 |